Clinical bottom line
Biologic therapies targeting type 2 inflammation pathways are emerging as promising corticosteroid-sparing options for allergic bronchopulmonary aspergillosis (ABPA), particularly in patients with asthma or cystic fibrosis. Current evidence suggests that biologics such as anti-IgE and anti-IL-5 agents can reduce exacerbations, improve lung function, and decrease corticosteroid dependence. However, high-quality randomized controlled trials remain limited, and biologics are generally considered adjunctive to standard antifungal and corticosteroid therapy. Updated clinical guidelines now incorporate biologics as potential options in refractory or corticosteroid-intolerant cases, emphasizing individualized treatment approaches (Agarwal et al., 2024; Kim et al., 2025; Darragh et al., 2023).
What the evidence shows
The 2024 revised ISHAM-ABPA guidelines (Agarwal et al.) acknowledge biologics as adjunctive therapies, particularly for patients with frequent exacerbations or corticosteroid-related adverse effects. Anti-IgE therapy (omalizumab) has demonstrated reductions in exacerbation frequency and corticosteroid requirements in observational studies and small trials.
Kim et al. (2025) review immunologic mechanisms and clinical data supporting biologics in ABPA, highlighting benefits of anti-IL-5 agents (mepolizumab, benralizumab) in reducing eosinophilic inflammation and improving respiratory symptoms, especially in cystic fibrosis populations.
Darragh et al. (2023) provide evidence from cohort studies showing corticosteroid-sparing effects of biologics, with improved asthma control and fewer hospitalizations.
Pediatric-focused guidelines (Mathew et al., 2023) also support biologic use in select children with ABPA and severe asthma, emphasizing safety and efficacy data.
Caveats and uncertainty
Most evidence derives from observational studies, case series, or small trials; large randomized controlled trials are lacking.
Optimal timing, dosing, and choice of biologic remain undefined.
Long-term safety and cost-effectiveness data are limited.
Biologics do not replace antifungal therapy and require careful patient selection.
Heterogeneity in ABPA phenotypes complicates generalization of findings.
How this may change practice
Clinicians should consider biologics as adjunctive options for ABPA patients with poor corticosteroid tolerance, frequent exacerbations, or persistent symptoms despite standard therapy.
Multidisciplinary evaluation including pulmonology, allergy/immunology, and infectious disease specialists is recommended.
Biologics may reduce corticosteroid exposure and associated morbidity, improving quality of life.
Ongoing monitoring for efficacy and adverse effects is essential.
Future guidelines will likely refine biologic indications as evidence accrues.